Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema

J Allergy Clin Immunol. 1980 Jan;65(1):75-9. doi: 10.1016/0091-6749(80)90181-5.

Abstract

Treatment with 17 alpha-methyltestosterone and with some synthetic androgens prevents attacks of hereditary angioedema (HAE). However, the potential hepatotoxicity of 17 alpha-alkylated androgens raises the problem of long-term prophylactic use of these agents. Therefore we compared the efficacy in preventing HAE attacks of 17 alpha-alkylated steroids (danazol and stanozolol) with non-17 alpha-alkylated derivatives (quinbolone, nandrolone decanoate and mesterolone). As the latter group proved ineffective, it seems that a drug's efficacy in preventing HAE attacks is connected to its 17 alpha-alkylation. Moreover, our long-term observations with the minimum effective dose of danazol seem to indicate the absence of important collateral effects.

MeSH terms

  • Adult
  • Androstadienes / administration & dosage
  • Angioedema / drug therapy
  • Angioedema / genetics*
  • Complement C1 Inactivator Proteins
  • Complement C4
  • Danazol / administration & dosage*
  • Danazol / adverse effects
  • Danazol / therapeutic use
  • Female
  • Humans
  • Long-Term Care
  • Male
  • Mesterolone / administration & dosage
  • Middle Aged
  • Nandrolone / administration & dosage
  • Pregnadienes / administration & dosage*
  • Stanozolol / administration & dosage*
  • Stanozolol / therapeutic use

Substances

  • Androstadienes
  • Complement C1 Inactivator Proteins
  • Complement C4
  • Pregnadienes
  • Mesterolone
  • Stanozolol
  • Nandrolone
  • Danazol
  • quinbolone